TITLE

Treatment helps control involuntary outbursts?

PUB. DATE
May 2010
SOURCE
Hospice Management Advisor;May2010, Vol. 15 Issue 5, p55
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents the new treatment for pseudobulbar affect (PBA), a neurological condition of involuntary expression of patient. Erik P. Pioro, director of the Section for ALS and Related Disorder at the Ohio Clinic, says that the abnormalities can affect the patient and caregiver well-being. The DMQ, a combination of two medications including dextromethorphan and low dose quinidine, improves the average test score by 2.7 points and controls the impairing condition suffered by patients.
ACCESSION #
50355177

 

Related Articles

  • Dextromethorphan Hydrobromide and Quinidine Sulfate Tablets (Nuedexta). Elliot, William T.; Chan, James // Internal Medicine Alert;12/29/2010, Vol. 32 Issue 24, p190 

    The article reports on the approval of the drug dextromethorphan (DEX)/quinidine (QUIN), a treatment for pseudobulbar affect, by the U.S. Food and Drug Administration (FDA).

  • Zenvia Posts Positive Phase III Results in PBA.  // Bioworld Week;8/17/2009, Vol. 17 Issue 33, p3 

    The article reports on the positive Phase III results in pseudobulbar affect (PBA) with the drug Zenvia from biotech company Avanir Pharmaceuticals Inc. in Aliso Viejo, California. It states that the results in PBA combine the dextromethorphan synthetic morphine derivative in Zenvia with the...

  • Dextromethorphan and Quinidine.  // AHFS Consumer Medication Information;Oct2017, p1 

    The combination of dextromethorphan and quinidine is used to treat pseudobulbar affect (PBA; a condition of sudden, frequent outbursts of crying or laughing that can not be controlled) in people with certain conditions such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease; condition...

  • Dextromethorphan/quinidine: Decreased platelet count: case report.  // Reactions Weekly;Nov2013, Issue 1477, p17 

    The article presents a case study of a man who experienced a decreased platelet count after being treated with dextromethorphan/quinidine for a traumatic brain injury.

  • Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia. Ballard, Clive; Sharp, Samantha; Corbett, Anne // JAMA: Journal of the American Medical Association;9/22/2015, Vol. 314 Issue 12, p1233 

    The article offer the author's insights on the effects of Quinidine and Dextromethorphan in treating agitation of Alzheimer's Disease patients with dementia. Topics mentioned inlude the use of nonpharmacological interventions in first-line treatment approach, the use of the combination between...

  • Clinical Study on Jin's Needling Treatment of Apoplectic Pseudobulbar Palsy. Xiaojun Chen; Lifang Chen; Zhanglian Wang; Zhen Fang; Xia Li // International Journal of Clinical Acupuncture;Apr-Jun2015, Vol. 24 Issue 2, p77 

    Objective: To observe the clinical curative effect of Jin's needling treatment on apoplectic Pseudobulbar Palsy. Methods: 80 patients diagnosed with apoplectic pseudobulbar paralysis were randomly divided into a treatment group and a control group with 40 cases in each group. On the basis of...

  • Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect. Yang, Lily; Deeks, Emma // Drugs;Jan2015, Vol. 75 Issue 1, p83 

    Fixed-dose dextromethorphan/quinidine capsules (Nuedexta) utilize quinidine to inhibit the metabolism of dextromethorphan, enabling high plasma dextromethorphan concentrations to be reached without using a larger dose of the drug. The drug combination is the first treatment to be approved for...

  • Availability and Use of Parenteral Quinidine Gluconate for Severe or Complicated Malaria.  // MMWR: Morbidity & Mortality Weekly Report;12/22/2000, Vol. 49 Issue 50, p1138 

    Deals with the use of the quinidine gluconate, a class 1a anti-arrhythmic agent, as parenteral antimalarial vaccine for severe or complicated malaria in the United States. Implications of the decline in the use of the vaccine; Several manufacturers of the vaccine.

  • Drug curbs emotional outbursts.  // Clinical Advisor;Apr2011, Vol. 14 Issue 4, p34 

    The article offers information on Nuedexta developed by Avanir, a drug that is used to control emotional outbursts. It says that Nuedexta is composed of dextromethorphan (DM), and quinidine sulfate. It is used to treat pseudodobulbar affect (PBA) and contraindicated to induced thrombocytopenia,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics